Bright Peak Therapeutics to Present Innovative Best-in-Class and Multifunctional Regulatory T Cell (Treg) Enhancers at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments GlobeNewswire October 20, 2022 – First presentation of BPT264, the only Treg-targeting IL-2 for autoimmune disease that is both IL2Rα-enhanced and IL2Rβ-dead, displaying best-in-class preclinical properties .
- First presentation of BPT264, the only Treg-targeting IL-2 for autoimmune disease that is both IL2Ra-enhanced and IL2Rß-dead, displaying best-in-class preclinical properties - - Introduction